Davey Daniel, MD, chief medical officer, OneOncology, speaks on the knowledge, infrastructure, and payer-related barriers that are limiting the use of genomic testing in the management of patients with lung cancer.
There remain several barriers impacting genomic testing and the use of precision medicine for lung cancer, which can delay patient care and lead to adverse outcomes, said Davey Daniel, MD, chief medical officer, OneOncology.
Transcript
As a lung cancer specialist, what has been your experience with patients who seek access to genomic testing to guide treatment?
[At] my personal practice, I found that fairly straightforward. I've been fortunate that I've had a series of clinical trials—and perhaps it's just payer mix and such—that I really feel like that as long as I have adequate tissue, I get great tissue testing. I've been an early adopter of using serum circulating tumor DNA for testing.
So I feel, in my practice, it's been fairly straightforward. But what I've learned [is] that it's not true across the country. When I talk to my colleagues that are in practices in California, just the payer structure is such that they can't get the testing they want.
I talk to other colleagues; they're reflex testing and they're iterative testing, where they do sequential testing, [and that] uses up all the tissue. So, those are real issues and it's delaying patient care—so we have to focus on that. I think physicians and medical oncologists totally understand the importance.
And when we look within OneOncology, we actually find really high testing levels and that most doctors are waiting until they have those results before dictating the first line of care. But I think it's clear that we need to make that faster, because some patients need to be treated quickly, and that any barriers to slowing that down may influence people to treat earlier than they would like to.
I do think there's a second component, and that's making sure there's appropriate interpretation. I think medical oncologists are pretty savvy, so driver mutations we can pick up pretty quickly. I think the next step we all have is identifying possible backup plans, including if there's a signature that suggests maybe a clinical trial option for that patient.
So, one thing at OneOncology we're doing is trying to just build out the precision medicine program, weekly molecular tumor boards. Hopefully that will make it easy for physicians to expand their knowledge, but also for that individual patient, focus on what the next steps are. We've been doing a series of educational tumor boards once a month on molecular cancer topics, and we'll continue that. But then we also continue weekly case-by-case reviews and discussions, and I've actually learned a huge amount from that.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Lack of Mutations Associated With Favorable Prognosis in MPN-U
April 25th 2024While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for myeloproliferative neoplasm, unclassifiable (MPN-U).
Read More
What We’re Reading: FDA Approves UTI Antibiotic; Ozempic, Wegovy Price Investigation; US Births Fall
April 25th 2024The FDA recently approved an antibiotic for the treatment of urinary tract infections (UTIs) in women; a Senate committee recently launched an investigation into the prices of Novo Nordisk’s diabetes and weight loss drugs; US births fell last year, resuming a national slide after a previous increase during the pandemic.
Read More